Pay in 4 interest-free payments of $5.52 Learn more
Ships within 48 hours · Estimated delivery Aug 15 - Aug 20
Currently, there is an ongoing randomised double-masked placebo-controlled trial, the SUMMIT trial, studying the efficacy and safety of tirzepatide, a dual agonist of glucose-dependent insulinotropic polypeptide and GLP-1 receptors, versus placebo in HFpEF patients with obesity (NCT04847557)
This table breaks it down clearly
Women are already the largest group of users, with a recent KFF poll finding that 15% of women versus 9% of men, are currently taking a GLP-1
Adverse reactions Reactions to drugs encompass a broad range of responses to medications, including drug allergy rashes
US$ 26.64
US$ 24.78
US$ 27.15
US$ 24.38
US$ 26.71
US$ 22.65
US$ 22.31
US$ 25.36
US$ 21.76
